Previous 10 | Next 10 |
NORTH CHICAGO, Illinois and COPENHAGEN, Denmark , June 10, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that AbbVie and Genmab have signed a broad collaboration agreement to jointly develop and commercialize three of Genmab's early-stage in...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
As expected, the European Commission approves a subcutaneous fixed-dose formulation of Johnson & Johnson's ( JNJ -1.1% ) Darzalex (daratumumab) for the treatment of multiple myeloma. More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks news, Read more ...
Genmab A/S (GNMSF) Q1 2020 Earnings Conference Call May 06, 2020, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Anthony Mancini - EVP & COO Conference Call Participants Trung Huynh - Crédit Suisse ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2020 Earnings Call May 6, 2020 , 12:00 p.m. ET Operator Continue reading
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q1 earnings Read more ...
Genmab (NASDAQ: GMAB ): Q1 GAAP EPS of DKK4.09. More news on: Genmab A/S, Genmab A/S, Earnings news and commentary, Tech stocks news, Read more ...
The FDA approves a subcutaneous formulation of Johnson & Johnson's ( JNJ -1.9% ) multiple myeloma med Darzalex (daratumumab). Originally, the CD38-directed cytolytic antibody was administered via intravenous infusion. More news on: Johnson & Johnson, Halozyme Therapeutics, Inc....
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of a subcutaneous formulation of Johnson & Johnson's ( JNJ -0.6% ) multiple myeloma med Darzalex (daratumumab). More news on: Johnson & Johnson, Genmab A/S, Healthcare stocks new...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...